Latest & greatest articles for hypertension

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hypertension or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hypertension and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hypertension

101. Effects of Bariatric Surgery in Obese Patients With Hypertension: The GATEWAY Randomized Trial (Gastric Bypass to Treat Obese Patients With Steady Hypertension)

Effects of Bariatric Surgery in Obese Patients With Hypertension: The GATEWAY Randomized Trial (Gastric Bypass to Treat Obese Patients With Steady Hypertension) 29133606 2017 11 14 1524-4539 2017 Nov 13 Circulation Circulation Effects of Bariatric Surgery in Obese Patients With Hypertension: The GATEWAY Randomized Trial (Gastric Bypass to Treat Obese Patients With Steady Hypertension). CIRCULATIONAHA.117.032130 10.1161/CIRCULATIONAHA.117.032130 BACKGROUND : Recent research efforts (...) on bariatric surgery have focused on metabolic and diabetes mellitus resolution. Randomized trials designed to assess the impact of bariatric surgery in patients with obesity and hypertension are needed. METHODS : In this randomized, single-center, nonblinded trial, we included patients with hypertension (using ≥2 medications at maximum doses or >2 at moderate doses) and a body mass index between 30.0 and 39.9 kg/m2 Patients were randomized to Roux-en-Y gastric bypass plus medical therapy or medical therapy alone

EvidenceUpdates2017

102. Correlation between health literacy and health-related quality of life in patients with hypertension, in Tehran, Iran, 2015–2016

Correlation between health literacy and health-related quality of life in patients with hypertension, in Tehran, Iran, 2015–2016 Electronic Physician (ISSN: 2008-5842) http://www.ephysician.ir November 2017, Volume: 9, Issue: 11, Pages: 5712-5720, DOI: http://dx.doi.org/10.19082/5712 Corresponding author: Assistant Professor Dr. Nadereh Naderiravesh, Department of Medical-Surgical Nursing, School of Nursing & Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Tel (...) is properly cited, the use is non-commercial and no modifications or adaptations are made. Page 5712 Correlation between health literacy and health-related quality of life in patients with hypertension, in Tehran, Iran, 2015-2016 Ahmad Johari Naimi 1 , Nadereh Naderiravesh 2 , Zahra Safavi Bayat 2 , Nezhat Shakeri 3 , Mahsa Matbouei 4 1 M.Sc. of Nursing, Department of Medical-Surgical Nursing, School of Nursing & Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran 2 Ph.D. of Nursing

Electronic physician2017 Full Text: Link to full Text with Trip Pro

103. Pulmonary hypertension in stiff left atrial syndrome: pathogenesis and treatment in one

Pulmonary hypertension in stiff left atrial syndrome: pathogenesis and treatment in one Pulmonary hypertension in stiff left atrial syndrome: pathogenesis and treatment in one Micha T. Maeder 1 * , Reto Nägele 1,2 , Philipp Rohner 2 and Daniel Weilenmann 1 1 Cardiology Department, Kantonsspital St. Gallen, Rorschacherstrasse 95, 9007, St. Gallen, Switzerland; 2 Department of Internal Medicine, Spital Grabs, Grabs, Switzerland Abstract We present the rare case of a patient with pulmonary (...) hypertension in the context of the stiff left atrial syndrome after extensive catheter ablation, a unique constellation characterized by high pulmonary artery and pulmonary artery wedge pressures due to left atrial dysfunction but normal left ventricular end-diastolic pressure, normal mitral valve, and absence pulmonary vein stenosis. This patient was surprisingly oligosymptomatic, however, which may have been due to a persistent post-puncture atrial septal defect, which may have allowed for controlled

ESC heart failure2017 Full Text: Link to full Text with Trip Pro

104. Factors Associated With Health-Related Quality of Life among Hypertensive Patients in Kathmandu, Nepal

Factors Associated With Health-Related Quality of Life among Hypertensive Patients in Kathmandu, Nepal 29164136 2018 11 13 2297-055X 4 2017 Frontiers in cardiovascular medicine Front Cardiovasc Med Factors Associated With Health-Related Quality of Life among Hypertensive Patients in Kathmandu, Nepal. 69 10.3389/fcvm.2017.00069 Nepal has a high prevalence of hypertension. While improving the overall health-related quality of life (HRQOL) is a central tenet to public health plans in developed (...) nations, this focus has yet to be articulated in Nepal. Therefore, this study aims to identify the factors associated with HRQOL among hypertensive patients in Nepal. The EuroQol-5Dimension HRQOL survey was administered to 180 hypertensive patients, attending the outpatient clinic at Shahid Gangalal National Heart Center in Kathmandu, Nepal. Multiple linear regression models, adjusted for age and sex, were used to identify factors associated with HRQOL. The mean age and EuroQol visual analytic scale

Frontiers in cardiovascular medicine2017 Full Text: Link to full Text with Trip Pro

105. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model

Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model 28775047 2017 08 04 2017 09 19 1399-3003 50 2 2017 Aug The European respiratory journal Eur. Respir. J. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. 1700740 10.1183/13993003.00740-2017 The 2015 European pulmonary hypertension (PH) guidelines propose a risk (...) stratification strategy for patients with pulmonary arterial hypertension (PAH). Low-, intermediate- and high-risk strata are defined by estimated 1-year mortality risks of <5%, 5-10% and >10%, respectively. This risk assessment strategy awaits validation.We analysed data from patients with newly diagnosed PAH enrolled into COMPERA (Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension), a European-based PH registry. An abbreviated version of the risk assessment strategy

EvidenceUpdates2017 Full Text: Link to full Text with Trip Pro

106. Is living in a gas-flaring host community associated with being hypertensive? Evidence from the Niger Delta region of Nigeria

Is living in a gas-flaring host community associated with being hypertensive? Evidence from the Niger Delta region of Nigeria 29225950 2018 11 13 2059-7908 2 4 2017 BMJ global health BMJ Glob Health Is living in a gas-flaring host community associated with being hypertensive? Evidence from the Niger Delta region of Nigeria. e000413 10.1136/bmjgh-2017-000413 Researchers have linked gas flaring to climate change, the hastening of the epidemiological transition and an upsurge in the prevalence (...) of non-communicable diseases. We sought to determine if a relationship exists between residing in a gas-flaring host community and hypertension. We conducted an analytical cross-sectional household survey among residents of 600 households in three gas-flaring and three non-gas-flaring host communities in the Niger Delta region of Nigeria. We took geo-coordinates, administered a modified WHO-STEPS questionnaire and built on Android mobile phones using Open-Data-Kit (ODK) software. We also took

BMJ global health2017 Full Text: Link to full Text with Trip Pro

107. Prevalence, awareness, treatment, and control of hypertension in China: data from 1·7 million adults in a population-based screening study (China PEACE Million Persons Project).

Prevalence, awareness, treatment, and control of hypertension in China: data from 1·7 million adults in a population-based screening study (China PEACE Million Persons Project). BACKGROUND: Hypertension is common in China and its prevalence is rising, yet it remains inadequately controlled. Few studies have the capacity to characterise the epidemiology and management of hypertension across many heterogeneous subgroups. We did a study of the prevalence, awareness, treatment, and control (...) of hypertension in China and assessed their variations across many subpopulations. METHODS: We made use of data generated in the China Patient-Centered Evaluative Assessment of Cardiac Events (PEACE) Million Persons Project from Sept 15, 2014, to June 20, 2017, a population-based screening project that enrolled around 1·7 million community-dwelling adults aged 35-75 years from all 31 provinces in mainland China. In this population, we defined hypertension as systolic blood pressure of at least 140 mm Hg

Lancet2017

108. Deep Venous Thrombosis among hypertensive patients in King Abdulaziz University (KAU) Hospital, Jeddah, Kingdom of Saudi Arabia

Deep Venous Thrombosis among hypertensive patients in King Abdulaziz University (KAU) Hospital, Jeddah, Kingdom of Saudi Arabia 29238486 2018 11 13 2008-5842 9 10 2017 Oct Electronic physician Electron Physician Deep Venous Thrombosis among hypertensive patients in King Abdulaziz University (KAU) Hospital, Jeddah, Kingdom of Saudi Arabia. 5472-5477 10.19082/5472 Deep venous thrombosis (DVT) is a frequent cardiovascular disorder. It is among the main causes of morbidity and mortality among (...) hospitalized patients and, at the same time, can be easily avoided. Studies clarified that there are a variety of factors which can be significantly associated with the development of DVT in hospitalized patients. to identify frequency and factors associated with occurrence of DVT among hypertensive patients referred to KAU hospital, Jeddah, Kingdom of Saudi Arabia. A cross-sectional hospital-based study was conducted from October 2016 to March, 2017. All hypertensive patients referred to or admitted

Electronic physician2017 Full Text: Link to full Text with Trip Pro

109. Prognostic Effect and Longitudinal Hemodynamic Assessment of Borderline Pulmonary Hypertension

Prognostic Effect and Longitudinal Hemodynamic Assessment of Borderline Pulmonary Hypertension 29071338 2018 11 13 2380-6591 2 12 2017 Dec 01 JAMA cardiology JAMA Cardiol Prognostic Effect and Longitudinal Hemodynamic Assessment of Borderline Pulmonary Hypertension. 1361-1368 10.1001/jamacardio.2017.3882 Pulmonary hypertension (PH) is diagnosed by a mean pulmonary arterial pressure (mPAP) value of at least 25 mm Hg during right heart catheterization (RHC). While several studies have

JAMA cardiology2017 Full Text: Link to full Text with Trip Pro

110. Blood pressure targets for the treatment of people with hypertension and cardiovascular disease.

Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. BACKGROUND: Hypertension is a prominent preventable cause of premature morbidity and mortality. People with hypertension and established cardiovascular disease are at particularly high risk, so reducing blood pressure below standard targets may be beneficial. This strategy could reduce cardiovascular mortality and morbidity but could also increase adverse events. The optimal blood pressure target (...) in people with hypertension and established cardiovascular disease remains unknown. OBJECTIVES: To determine if 'lower' blood pressure targets (≤ 135/85 mmHg) are associated with reduction in mortality and morbidity as compared with 'standard' blood pressure targets (≤ 140 to 160/ 90 to 100 mmHg) in the treatment of people with hypertension and a history of cardiovascular disease (myocardial infarction, angina, stroke, peripheral vascular occlusive disease). SEARCH METHODS: The Cochrane Hypertension

Cochrane2017

111. The Spectrum of Subclinical Primary Aldosteronism and Incident Hypertension: A Cohort Study.

The Spectrum of Subclinical Primary Aldosteronism and Incident Hypertension: A Cohort Study. Background: Primary aldosteronism is recognized as a severe form of renin-independent aldosteronism that results in excessive mineralocorticoid receptor (MR) activation. Objective: To investigate whether a spectrum of subclinical renin-independent aldosteronism that increases risk for hypertension exists among normotensive persons. Design: Cohort study. Setting: National community-based study (...) . Participants: 850 untreated normotensive participants in MESA (Multi-Ethnic Study of Atherosclerosis) with measurements of serum aldosterone and plasma renin activity (PRA). Measurements: Longitudinal analyses investigated whether aldosterone concentrations, in the context of physiologic PRA phenotypes (suppressed, ≤0.50 µg/L per hour; indeterminate, 0.51 to 0.99 µg/L per hour; unsuppressed, ≥1.0 µg/L per hour), were associated with incident hypertension (defined as systolic blood pressure ≥140 mm Hg

Annals of Internal Medicine2017

112. Noninvasive Clinical Predictors of Portal Hypertensive Gastropathy in Patients with Liver Cirrhosis

Noninvasive Clinical Predictors of Portal Hypertensive Gastropathy in Patients with Liver Cirrhosis 29085790 2018 11 13 2450-131X 5 3 2017 Sep Journal of translational internal medicine J Transl Int Med Noninvasive Clinical Predictors of Portal Hypertensive Gastropathy in Patients with Liver Cirrhosis. 169-173 10.1515/jtim-2017-0025 Portal hypertensive gastropathy (PHG) is described endoscopically as "mosaic-like appearance" of gastric mucosa with or without the red spots. It can only (...) , specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of PSR were 87.23%, 5.88%, 83.67%, 7.69%, and 74.7%, respectively, and those of RLAR were 28.72%, 70.59%, 84.38%, 15.19%, and 35.14%, respectively. PSR is better predictor of PHG than RLAR but at the expense of relatively lower specificities and NPV likely because of underlying pathophysiology (portal hypertension) which is similar for esophageal varices, PHG, and ascites. Mandhwani Rajesh R Departments

Journal of translational internal medicine2017 Full Text: Link to full Text with Trip Pro

113. Calcium supplementation commencing before or early in pregnancy, or food fortification with calcium, for preventing hypertensive disorders of pregnancy.

Calcium supplementation commencing before or early in pregnancy, or food fortification with calcium, for preventing hypertensive disorders of pregnancy. BACKGROUND: Pre-eclampsia is considerably more prevalent in low- than high-income countries. One possible explanation for this discrepancy is dietary differences, particularly calcium deficiency. Calcium supplementation in the second half of pregnancy reduces the serious consequences of pre-eclampsia and is recommended by the World Health (...) -pregnancy, on pre-eclampsia and other hypertensive disorders, maternal morbidity and mortality, as well as fetal and neonatal outcomes. SEARCH METHODS: We searched the Cochrane Pregnancy and Childbirth Trials Register (10 August 2017), PubMed (29 June 2017), ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform (ICTRP) (10 August 2017) and reference lists of retrieved studies. SELECTION CRITERIA: Randomised controlled trials of calcium supplementation or food fortification which

Cochrane2017

114. Netarsudil plus latanoprost (Roclatan) for glaucoma or ocular hypertension

Netarsudil plus latanoprost (Roclatan) for glaucoma or ocular hypertension Netarsudil plus latanoprost (Roclatan) for glaucoma or ocular hypertension ‐ NIHR Innovation Observatory ☰ Menu Search Filter by Specialty Filter by Year Netarsudil plus latanoprost (Roclatan) for glaucoma or ocular hypertension September 2017 Technology Description: Glaucoma describes a group of disorders characterised by sight loss. Glaucoma is generally associated with high pressure in the liquids inside the eye

NIHR Innovation Observatory2017

115. Hierarchical Modeling of Patient and Physician Determinants of Blood Pressure Outcomes in Hypertensive Patients with and without Diabetes: Pooled Analysis of Six Observational Valsartan Studies with 15,282 Evaluable Patients

Hierarchical Modeling of Patient and Physician Determinants of Blood Pressure Outcomes in Hypertensive Patients with and without Diabetes: Pooled Analysis of Six Observational Valsartan Studies with 15,282 Evaluable Patients 29142906 2018 11 13 2356-6981 2017 2017 International journal of chronic diseases Int J Chronic Dis Hierarchical Modeling of Patient and Physician Determinants of Blood Pressure Outcomes in Hypertensive Patients with and without Diabetes: Pooled Analysis of Six (...) approximately 90 days of therapy. The modeling analyses identified several common and different patient- and physician-related determinants of BP outcomes for both groups, many of which are modifiable or clinically manageable. Through varying in terms of association and influence between the diabetic and nondiabetic groups, patient-related determinants included age, BP at diagnosis of hypertension, risk factors, valsartan regimen, concomitant antihypertensive treatment, and adherence; and physician-related

International journal of chronic diseases2017 Full Text: Link to full Text with Trip Pro

116. Establishing funding priorities for hypertension research: a modest proposal

Establishing funding priorities for hypertension research: a modest proposal 28947614 2018 01 29 2018 11 13 1524-4563 70 5 2017 11 Hypertension (Dallas, Tex. : 1979) Hypertension Establishing Funding Priorities for Hypertension Research: A Modest Proposal. 893-896 10.1161/HYPERTENSIONAHA.117.10100 Kotchen Theodore A TA From the Department of Medicine, Medical College of Wisconsin, Milwaukee. tkotchen@mcw.edu. eng KL2 TR001438 TR NCATS NIH HHS United States UL1 TR001436 TR NCATS NIH HHS United (...) States Editorial Research Support, N.I.H., Extramural 2017 09 25 United States Hypertension 7906255 0194-911X IM MMWR Morb Mortal Wkly Rep. 2016 Nov 18;65(45):1261-1264 27855138 Acad Med. 2015 Jul;90(7):861-5 26414054 JAMA. 2004 Feb 18;291(7):836-43 14970062 JAMA. 1967 Dec 11;202(11):1028-34 4862069 Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):5773-7 24733905 JAMA. 1970 Aug 17;213(7):1143-52 4914579 JAMA. 2003 Mar 12;289(10 ):1278-87 12633190 J Am Coll Cardiol. 2013 Mar 26;61(12):1259-67 23500328

Hypertension (Dallas, Tex. : 1979)2017 Full Text: Link to full Text with Trip Pro

117. Trends for prevalence and incidence of resistant hypertension: population based cohort study in the UK 1995-2015.

Trends for prevalence and incidence of resistant hypertension: population based cohort study in the UK 1995-2015. Objective To estimate the incidence and prevalence of resistant hypertension among a UK population treated for hypertension from 1995 to 2015. Design Cohort study. Setting Electronic health records from the UK Clinical Practice Research Datalink in primary care. Participants 1 317 290 users of antihypertensive drugs with a diagnosis of hypertension. Main outcome measures Resistant (...) hypertension was defined as concurrent use of three antihypertensive drugs inclusive of a diuretic, uncontrolled hypertension (≥140/90 mm Hg), and adherence to the prescribed drug regimen, or concurrent use of four antihypertensive drugs inclusive of a diuretic and adherence to the prescribed drug regimen. To determine incidence, the numerator was new cases of resistant hypertension and the denominator was person years of those with treated hypertension and at risk of developing resistant hypertension. To

BMJ2017

118. Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study.

Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study. BACKGROUND: Carotid baroreflex activation lowers blood pressure and might have potential application for the treatment of resistant hypertension. We did a proof-of-principle trial with a novel endovascular baroreceptor amplification device, MobiusHD (Vascular Dynamics, Mountain View, CA, USA), in patients with resistant hypertension. METHODS: CALM-FIM_EUR was a prospective, first (...) -in-human, open-label study done at six European centres. Eligible patients were adults with resistant hypertension (office systolic blood pressure ≥160 mm Hg despite taking at least three antihypertensive agents, including a diuretic). MobiusHD devices were implanted unilaterally in the internal carotid artery. The primary endpoint was the incidence of serious adverse events at 6 months. Secondary endpoints included changes in office and 24 h ambulatory blood pressure. This trial is registered

Lancet2017

119. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial.

Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. BACKGROUND: Previous randomised renal denervation studies did not show consistent efficacy in reducing blood pressure. The objective of our study was to evaluate the effect of renal denervation on blood pressure in the absence of antihypertensive medications. METHODS: SPYRAL HTN-OFF MED

Lancet2017

120. Does early detection of renovascular hypertension improve outcomes?

Does early detection of renovascular hypertension improve outcomes? Does early detection of renovascular hypertension improve outcomes? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Does early detection of renovascular hypertension improve outcomes? View/ Open Date 2017-05 Format Metadata Abstract Does early (...) detection of renovascular hypertension improve outcomes? Evidence-based answer: Probably not. Finding atherosclerotic renal artery stenosis (ARAS) and treating with revascularization has shown no clinically significant improvement in rates of myocardial infarction (MI), renal function, congestive heart failure (CHF), or stroke compared with medical treatment of renovascular hypertension (SOR: A, metaanalysis of RCTs). Recommendations to revascularize asymptomatic ARAS are controversial, calling

Evidence Based Practice 2017